Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
The Role of Hypofractionated Radiotherapy in Modern Oncology
share announcement

The Role of Hypofractionated Radiotherapy in Modern Oncology

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 5171

Special Issue Editors

Dr. Mateusz Spałek

E-Mail Website
Guest Editor
Department of Radiotherapy I, Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, W.K. Roentgena 5 Street, 02-781 Warsaw, Poland
Interests: soft tissue sarcoma; bone tumors; bone metastases; melanoma; skin cancer; SBRT; hypofractionation
Special Issues, Collections and Topics in MDPI journals
Dr. Aleksandra Napieralska

E-Mail Website
Guest Editor
Radiotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology, 44-102 Gliwice, Poland
Interests: pediatric radiation oncology; hypofractionated radiotherapy; prostate cancer; central nervous system tumors
Dr. Bartłomiej Tomasik

E-Mail Website
Guest Editor
Department of Oncology and Radiotherapy, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
Interests: biomarkers; cancer; cell biology; cell cycle; DNA repair; epigenetics; genetics; immunotherapy; molecular biology; radiation oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Advances in current radiation oncology enabled more precise dose delivery with significant sparing of surrounding healthy tissues. Thus, the fear of late complications associated with a higher dose per fraction was drastically reduced. Moreover, radiobiological research suggested more complex interactions between various fraction doses with modern systemic treatments such as immunotherapy than those calculated using radiobiological models. Various regimens of hypofractionated radiotherapy were and are investigated in various clinical trials that confirmed their safety and efficacy. Nevertheless, some fields are still underexplored. Furthermore, little is known about the optimal combination of hypofractionated regimens with other methods of cancer treatment. This Special Issue includes original reports and reviews that highlight biological and clinical aspects of hypofractionation in modern oncology. We also welcome studies regarding ultra-hypofractionation (SBRT, SRS).

The main areas of interest are:

  • The biological basis of hypofractionation;
  • Novel indications for hypofractionated radiotherapy;
  • The combination of hypofractionated regimens with systemic treatment and radiosensitizers.

Dr. Mateusz Spałek
Dr. Aleksandra Napieralska
Dr. Bartłomiej Tomasik
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 265 KiB  
Article
Ultra-Hypofractionation for Whole-Breast Irradiation in Early Breast Cancer: Interim Analysis of a Prospective Study
by Valeria Sigaudi, Micol Zannetti, Eleonora Ferrara, Irene Manfredda, Eleonora Mones, Gianfranco Loi, Marco Krengli and Pierfrancesco Franco
Biomedicines 2022, 10(10), 2568; https://doi.org/10.3390/biomedicines10102568 - 13 Oct 2022
Cited by 8 | Viewed by 2615
Abstract
We report on the early clinical outcomes of a prospective series of early breast cancer (EBC) patients treated with ultra-hypofractionated post-operative whole-breast irradiation (WBI) after breast-conserving surgery (BCS) and axillary management. Primary endpoints were patient’s compliance and acute toxicity. Secondary endpoints included physician-rated [...] Read more.
We report on the early clinical outcomes of a prospective series of early breast cancer (EBC) patients treated with ultra-hypofractionated post-operative whole-breast irradiation (WBI) after breast-conserving surgery (BCS) and axillary management. Primary endpoints were patient’s compliance and acute toxicity. Secondary endpoints included physician-rated cosmesis and ipsilateral breast tumour recurrence (IBTR). Acute toxicity was evaluated at the end of WBI, 3 weeks and 6 months thereafter, according to the Common Terminology Criteria for Adverse Events (v. 5.0). Patients were treated between September 2021 and May 2022. The treatment schedule for WBI consisted of either 26 Gy in 5 fractions over one week (standard approach) or 28.5 Gy in 5 fractions over 5 weeks (reserved to elders). Inverse planned intensity-modulated radiation therapy (IMRT) was used employing a static technique. A total of 70 patients were treated. Fifty-nine were treated with the 26 Gy/5 fr/1 w and 11 with the 28.5 Gy/5 fr/5 ws schedule. Median age was 67 and 70 in the two groups. Most of the patients had left-sided tumours (53.2%) in the 26 Gy/5 fr/1 w or right-sided lesions (63.6%) in the 28.5 Gy/5 fr/5 ws group. Most of the patients had a clinical T1N0 disease and a pathological pT1pN0(sn) after surgery. Ductal invasive carcinoma was the most frequent histology. Luminal A intrinsic subtyping was most frequent. Most of the patients underwent BCS and sentinel lymph node biopsy and adjuvant endocrine therapy. All patients completed the treatment program as planned. Maximum detected acute skin toxicities were grade 2 erythema (6.7%), grade 2 induration (4.4%), and grade 2 skin colour changes. No early IBTR was observed. Ultra-hypofractionated WBI provides favourable compliance and early clinical outcomes in EBC after BCS in a real-world setting. Full article
(This article belongs to the Special Issue The Role of Hypofractionated Radiotherapy in Modern Oncology)
11 pages, 907 KiB  
Article
Ultra-Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer: Clinical Outcomes, Patterns of Recurrence, Feasibility of Definitive Salvage Treatment, and Competing Oncological Risk
by Marcin Miszczyk, Monika Szołtysik, Maja Hasterok, Gregor Goldner, Paweł Rajwa, Agnieszka Namysł-Kaletka, Aleksandra Napieralska, Małgorzata Kraszkiewicz, Małgorzata Stąpór-Fudzińska, Bartłomiej Tomasik, Grzegorz Woźniak, Grzegorz Głowacki, Konrad Kaminiów, Matthias Moll, Łukasz Magrowski and Wojciech Majewski
Biomedicines 2022, 10(10), 2446; https://doi.org/10.3390/biomedicines10102446 - 30 Sep 2022
Cited by 3 | Viewed by 1910
Abstract
A cohort of 650 patients treated for localized prostate cancer (PCa) with CyberKnifeTM ultra-hypofractionated radiotherapy between 2011 and 2018 was retrospectively analyzed in terms of survival, patterns of failure, and outcomes of second-line definitive salvage therapies. The analysis was performed using survival [...] Read more.
A cohort of 650 patients treated for localized prostate cancer (PCa) with CyberKnifeTM ultra-hypofractionated radiotherapy between 2011 and 2018 was retrospectively analyzed in terms of survival, patterns of failure, and outcomes of second-line definitive salvage therapies. The analysis was performed using survival analysis including the Kaplan–Meier method and Cox regression analysis. At a median follow-up of 49.4 months, the main pattern of failure was local–regional failure (7.4% in low-, and 13% in intermediate/high-risk group at five years), followed by distant metastases (3.6% in low-, and 6% in intermediate/high-risk group at five years). Five-year likelihood of developing a second malignancy was 7.3%; however, in the vast majority of the cases, the association with prior irradiation was unlikely. The 5-year overall survival was 90.2% in low-, and 88.8% in intermediate/high-risk patients. The independent prognostic factors for survival included age (HR 1.1; 95% CI 1.07–1.14) and occurrence of a second malignancy (HR 3.67; 95% CI 2.19–6.15). Definitive local salvage therapies were feasible in the majority of the patients with local–regional failure, and uncommonly in patients with distant metastases, with an estimated second-line progression free survival of 67.8% at two years. Competing oncological risks and age were significantly more important for patients’ survival compared to primary disease recurrence. Full article
(This article belongs to the Special Issue The Role of Hypofractionated Radiotherapy in Modern Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop